We obtained lung tissues from three non-LAM patients, three LAM patients treated without sirolimus, and four LAM patients treated with sirolimus to further evaluate the effect of sirolimus, a mTOR inhibitor. Here, MTOR is linked to lymphangioleiomyomatosis.